Supplementary Figure 2. Scheme for competitive chemoproteomics experiments in ARPE-19 cells. (a and b)
Live cells are pretreated with an unmodified inhibitor (i.e., BACE inhibitor), or an equivalent volume of DMSO, before photoaffinity labeling with PF-7802. Proteins bound by the inhibitor are impeded from binding to PF-7802. For each specifically labeled protein, a decrease in signal is observed in inhibitor pretreated samples, whereas equal signal in control and inhibitor pretreated samples indicates a nonspecifically labeled or enriched protein. Inhibitor binding can be detected as a decrease in fluorescence intensity after click chemistry with TAMRA-azide and analysis by SDS-PAGE (a, in-gel fluorescence), or a decrease in MS1 signal intensity after click chemistry with biotin-azide, enrichment of labeled proteins with streptavidin, on-bead trypsin digestion, and analysis by LC-MS/MS (b, SILAC mass spectrometry). Figure 5 . PF-7802 labeling of purified mature CatD and proCatD. 250 nM of purified human mature CatD, or proCatD, was pretreated with a range of PF-9283 concentrations in NaOAc buffer (pH 4.5), followed by photoaffinity labeling with PF-7802 (100 nM), click chemistry with TAMRA-azide, and in-gel fluorescence analysis. PF-7802 labeling of mature CatD was concentration-dependently competed by pretreatment with PF-9283, indicating specific labeling. In contrast, PF-7802 labeling of proCatD was weaker, and could not be competed by pretreatment with PF-9283, indicating non-specific labeling. Representative gel slice from in-gel fluorescence analysis (top) and quantification (bottom, red) of LY2811376 inhibition of purified CatD enzyme determined with the PF-7802 probe. These probe-based IC50 values were determined by pretreating purified human CatD (250 nM) with a range of LY2811376 concentrations followed by incubation with PF-7802 (100 nM, 30 min), UV irradiation, and click chemistry with TAMRA-azide. Note the similarity in enzyme IC50 values determined using the PF-7802 probe (red) compared to that determined from a biochemical substrate assay with purified protein (black), contrasting with the differences seen in Exposure-response plots comparing predicted in vivo inhibition and ocular toxicity. Target occupancy was used as a surrogate to predict in vivo inhibition and was calculated using an Emax equation based on in vivo average unbound plasma concentrations (Cp,u) and either BACE1 enzyme (a), BACE1 cellular (b), or BACE2 enzyme (c) IC50 values of inhibitors. Maximum achievable target occupancy was assumed to be 100% and, where applicable, competitive binding was assumed between parent and metabolite molecules. Safety studies were conducted with daily dosing in rats with the exception of two doses in dogs (indicated in parentheses). Outcomes were considered positive (red symbols) if at least one animal per cohort (n = 4 -6 for rats, n = 2 for dogs) had accumulated autofluorescent granules in the RPE cytoplasm (as determined by fluorescence microscopy) and negative (blue symbols) if there was no ocular pathology observed. See Supplementary Figure 14 for selected retinal histology images and Supplementary Top hits in proteomic analysis of RPE tissue from PF-9283-treated rats. Analysis was performed on tryptic digests of RPE tissue prepared from rats dosed daily for 14 days with 80 mg kg -1 PF-9283. Peptide spectral matches (PSM) of the above 11 identified proteins (of 391 total identified proteins) were changed more than 1.5-fold (P < 0.01) compared to vehicle controls. Average PSM were calculated from 6 LCMS runs consisting of 2 technical replicates of n = 3 RPE tissues per group, and limited to those proteins with at least 5 average PSM in both treated and control samples. Significant differences were determined using a two-tailed t-test.
Supplementary

PF-9283 (4)
PF Compounds 15, 18 and 23 were synthesized as previously described 1 .
Synthesis of photoaffinity probe PF-7802 (6).
N-{(4aR,6R,8aS)-8a-(2,4-Difluorophenyl)-6-[({4-[4-(prop-2-yn-1-yloxy)benzoyl]benzyl}oxy)methyl]-4,4a,5,6,8,8a-hexahydropyrano[3,4-d][1,3]thiazin-2-yl}benzamide (17).
To a vigorously stirring solution of 15 (465 mg, 1.11 mmol) in THF (4 mL) at room temperature was added sodium hydride (135 mg, 3.38 mmol, 60% dispersion in mineral oil) in portions. The mixture was stirred at room temperature for 30 minutes. Next, 16 (370 mg, 1.12 mmol) was added in one portion and the mixture was stirred at room temperature for 1 hour, then heated to 40 °C for 1.5 hours. The reaction mixture was cooled to room temperature, quenched with aqueous KHSO 4 solution (0.5 M, 20 mL), and extracted with EtOAc (3x). The combined organic extracts were washed with brine (1x), dried with anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel chromatography (EtOAc/heptane) to afford 17 (525 mg, 71% yield) as a white solid. 1 ((4S,4aR,6R,8aS)-2-amino-8a-(2,4-difluorophenyl)-4-(fluoromethyl)-4,4a,5,6,8,8a-hexahydropyrano[3,4-d][1,3]thiazin-6-yl)isoxazol-3-yl)methanol (12, PF-3763) . A solution of 22 (11.1 mg, 24.4 μmol) in EtOH (1.5 mL) was cooled to 0 °C. Sodium borohydride (2.7 mg, 73 μmol) was then added in one portion. The ice bath was removed and the mixture was stirred at room temperature for 2 hours, after which LCMS indicated consumption of starting material. EtOAc was added and the mixture was washed with saturated aqueous NH 4 Cl solution (2x) and brine (1x). The organic extract was dried with anhydrous MgSO 4 , filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel chromatography (2 N NH 3 in methyl 2- ((4S,4aR,6R,8aS)-2-benzamido-8a-(2,4-difluorophenyl)-4-(fluoromethyl)-4,4a,5,6,8,8a-hexahydropyrano[3,4-d][1,3]thiazin-6-yl)oxazole-4-carboxylate (25) . To a solution of 24 (820 mg, 1.45 mmol) in CH 2 Cl 2 (29 mL) at −20 °C was added Deoxo-Fluor (417 mg, 1.88 mmol) and the mixture was stirred at −20 °C for 50 minutes. Bromotrichloromethane (0.53 mL, 5.4 mmol) and DBU (0.84 mL, 5.4 mmol) were added and the mixture was then warmed to 0 °C and stirred overnight. The mixture was diluted with saturated aqueous NaHCO 3 solution and extracted with CH 2 Cl 2 (3x). The combined organic extracts were dried with anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel chromatography (EtOAc/heptane) to afford 25 (200 mg, 25% yield) as a white solid. 1 ((4S,4aR,6R,8aS)-2-amino-8a-(2,4-difluorophenyl)-4-(fluoromethyl)-4,4a,5,6,8,8a-hexahydropyrano[3,4-d][1,3 ]thiazin-6-yl)oxazol-4-yl)methanol (13, PF-7152). A solution of 25 (36 mg, 66 μmol) in EtOH (1.5 mL) was cooled to 0 °C. Sodium borohydride (7.5 mg, 0.20 mmol) was then added in one portion. The ice bath was removed and the mixture was stirred at room temperature for 2 hours, after which LCMS indicated consumption of starting material. EtOAc was added and the mixture was washed with saturated aqueous NH 4 Cl solution (2x) and brine (1x). The organic layer was dried with anhydrous MgSO 4 , filtered, and concentrated under reduced pressure. To the crude solid was added propylamine (1 mL) and the mixture was stirred at room temperature overnight, then heated to 40 °C for 1 hour, after which LCMS indicated consumption of starting material. The mixture was then concentrated under reduced pressure. The crude reside was purified by silica gel chromatography (2N NH 3 in MeOH/EtOAc) to afford 13 (25 mg, 92% yield over 2 steps) as a white solid. 1 
